Abstract-Liddle syndrome is considered a rare Mendelian hypertension. We have previously described 3 reportedly unrelated families, native of an Italian area around the Strait of Messina, carrying the same mutation (βP617L) of the epithelial sodium channel. The aims of our study were (1) to evaluate whether a close genomic relationship exists between the 3 families through the analysis of mitochondrial DNA and Y chromosome; and (2) to quantify the genomic relatedness between the patients with Liddle syndrome belonging to the 3 families and assess the hypothesis of a mutation shared through identity by descent. HVRI (the hypervariable region I) of the mitochondrial DNA genome and the Y chromosome short tandem repeats profiles were analyzed in individuals of the 3 families. Genotyping 542 585 genomewide single nucleotide polymorphisms was performed in all the patients with Liddle syndrome of the 3 families and some of their relatives. A panel of 780 healthy Italian adult samples typed for the same set of markers was used as controls.
F
irst described by Grant Liddle in 1963, Liddle syndrome (LS) is a hereditary condition, transmitted in an autosomal-dominant mode. 1 Its main clinical features include early onset of salt-sensitive hypertension, increased incidence of premature cardio-and cerebrovascular events, hypokalemic metabolic alkalosis, suppression of both renin and aldosterone secretion, and unresponsiveness to mineralocorticoid receptor antagonists, as opposed to the response to epithelial sodium channel (ENaC) inhibitors (ie, amiloride and triamterene). [1] [2] [3] Patients with LS are most often diagnosed between 10 and 30 years of age, but diagnosis is sometimes made earlier. LS occurs worldwide, with no apparent ethnic or sex predilection, and is classified by Orphanet as a rare disease, with an estimated prevalence of <1/10 6 within the global population (http://www. orpha.net/consor/cgi-bin/OC_Exp.php?Expert=526).
The mutations to date identified in LS cause constitutive activation of ENaC, which is composed of 3 homologous subunits, α, β, and γ, sharing ≈30% to 40% sequence identity. Each subunit is encoded by a specific gene (SCNN1A, SCNN1B, and SCNN1G, respectively) containing 13 exons. SCNN1A is located on 12p13.31 while SCNN1G and SCNN1B reside within a common 400-kb fragment on human chromosome 16p13-p12. Each ENaC subunit consists of 2 transmembrane domains, a large extracellular loop, and short cytoplasmic amino and carboxyl termini. [4] [5] [6] ENaC is expressed in the apical membrane of the principal cells of the aldosterone-sensitive distal nephron (ASDN), which comprises the late distal convolute tubule, the connecting tubule, and the entire collecting duct. ENaC, which is highly selective for Na + ions and inhibited by amiloride, February 2018
mediates the rate-limiting step in Na + absorption in the ASDN. The activity of ENaC depends on channel open probability (Po) and on the number of channels expressed at the apical membrane of ASDN principal cells. Aldosterone, which is the main regulator of ENaC, increases both the number of ENaCs expressed at the apical membrane and the channel Po. [7] [8] [9] To our knowledge, 29 LS-causing alleles have been reported to date, occurring in familial or sporadic cases. 10, 11 Apart from γENaC N530S and αENaC C479R, which increase the channel Po without changing the cell surface expression of ENaC, 11, 12 all the other mutations cluster within exon 13 of either SCNN1B or SCNN1G genes and are frameshift or nonsense or missense mutations that delete or alter a proline-rich PY motif, corresponding to the sequence PPPXY (where X is any amino acid) in the cytoplasmic C-terminus of the β or γ subunit. Of the 22 β-subunit mutations, 12 cause deletion of the PY motif, and 10 alter the sequence of the PY motif. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The PY motif plays a fundamental role in the internalization of ENaCs. Indeed, PY motifs of all the 3 ENaC subunits are the recognition site for the ubiquitin-protein-ligase Nedd4-2, which interacts with these motifs and ubiquitinates ENaC. Ubiquitination targets the ENaC for internalization and degradation, thus decreasing the number of ENaC expressed in the apical membrane. Mutations causing deletion or alteration of the PY motif prevent Nedd4-2 binding to ENaC. As a consequence, internalization and degradation of ENaC fail to occur, resulting in increased density of ENaC at the apical membrane of the ASDN. In addition to affecting the number of channels at the membrane, LS mutations also increase channel Po. 24 The increased ENaC activity in the apical surface of ASDN leads to a greater Na + reabsorption, plasma volume expansion, high blood pressure, and consequent decrease in renin and aldosterone secretion. In addition, the increased Na + reabsorption through ENaC generates a transepithelial lumen-negative voltage that drives K + secretion across the apical membrane, resulting in hypokalemic metabolic alkalosis. 8 Here, we analyze 3 previously reported families affected by LS caused by the same allele (βENaC P617L). The 3 families were native of a limited area of Italy, consisting of the 2 neighboring Provinces of Messina (Sicily) and Reggio Calabria (Calabria) located on the shores of the Messina Strait and were reportedly unrelated. Considering the rarity of LS, the lack of other reports of the βP617L mutation, and the restricted geographical area of origin shared by the 3 families, we checked the hypothesis that the 3 kindreds were carrying a mutation identical by descent. We, therefore, investigated, using genome-wide analyses, whether the LS-causing allele shared by the 3 probands and some of their relatives is a consequence of recurrent mutation or identity by descent and, in the latter case, how many affected individuals should be expected based on coalescent theory and forward simulation.
Indeed, estimating the number of generations that separate reportedly unrelated patients has important consequences on the prediction of the number of additional affected individuals yet to be diagnosed in a given population source. Previously, successful strategies were deployed to apply evolutionary inference to tackle this problem. 25, 26 Particularly, approaches based on coalescent theory were adopted, where the convergence of the alleles of a given locus to their common ancestor from an earlier time is used to make inferences on the evolutionary history of the examined DNA sequence and, hence, on the genetic relationships of the screened probands.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. Scripts from Y. Diekmann are available here: https://github.com/ydiekmann/ Pagani_Hypertension_2017
Probands Discovery and Sampling
Some of us (E. Rossi, E. Farnetti, B. Casali, F. Mantero) have previously identified a novel allele of the β subunit of ENaC (βP617L) causing LS in a proband whose paternal line was strongly suspected of carrying the allele. Expression of this ENaC variant in Xenopus oocytes caused a 3-fold increase in amiloride-sensitive Na + current compared with wild-type channels. 15 Later, the same group of authors found a second family carrying the same allele. 27 Last, a third family carrying the βP617L allele was recently identified by some other members of our current group (M. Rondinelli, A. Caretto, F. Novara, O. Zuffardi). 28 All subjects participating in the study provided their informed consent. The study was approved by the Ethics Committees of Santa Maria Nuova Hospital, Reggio Emilia, and MultiMedica Hospital, Sesto San Giovanni, Milan, respectively.
Genome-Wide Genotyping
Genomic DNA of the following samples (A IV-1, A III-2, A II-3, B V-1, B IV-2, B IV-3, B IV-4, B III-3, C IV-1, C III-2, C III-3, C II-2; see Figure 1 for their family trees) was quantified with the Quant-iT dsDNA Broad-Range Assay Kit (Invitrogen Life Technologies, Carlsbad, CA), and 200 ng of DNA were used to genotype 542 585 genomewide single nucleotide polymorphisms with the CoreExomeChip v.1.1 Array (Illumina, San Diego, CA). A panel of 780 healthy Italian adult samples typed for the same set of markers was used as controls and was already described elsewhere. 29 Control samples showing >1% missing genotypes, as well as those presenting discordant genetic/ ascertained sex (as revealed by comparison of each individual's mean homozygosity rate across X-chromosome markers with the expected rate), were removed from subsequent analyses. Moreover, autosomal heterozygosity rate per individual was assessed, and subjects with excessive or reduced proportion of heterozygote genotypes (ie, with values exceeding±3SDs from the mean) were filtered out. Further quality checks (PLINK commands -geno 0.1 -irem 0.08) and phasing were then performed on the entire data set (ie, including both healthy and disease individuals) to avoid batch effects.
mtDNA and Y Chromosome Analyses
HVRI (the hypervariable region I) of the mitochondrial DNA (mtDNA) genome and the 17 Y chromosome short tandem repeats profiles were analyzed in individuals from the 3 families with LS. Moreover, the complete mitochondrial genomes of 2 probands (A IV-1 and C IV-1) were sequenced to confirm the haplogroup inferred from the HVRI sequence. The mitochondrial genomes were sequenced with the Ion PGM System (Life Technologies, Grand Island, NY) taking advantage of an optimized protocol. 
Results
Sequencing analysis had previously detected a heterozygous C to T allele at codon 617 in exon 13 of SCNN1B in A IV-1, B V-1, B IV-2, B IV-3, B III-3, C IV-1, C III-2, C III-3, and C II-2. Therefore, screening the 3 probands' relatives led to the identification of 6 more carriers of the same allele. The mutant allele is predicted to replace the second proline with leucine in the sequence 616 PPPXY 620 (PY motif) of the β subunit (β P617L mutation). Each of the 3 families was characterized by an early onset of hypertension and premature cardiovascular events in several members across generations, which is consistent with an autosomal-dominant pattern of inheritance (Figure 1 ).
Age at presentation of hypertension ranged from 11 to 31 years. The time lapse between the ascertainment of hypertension and diagnosis of LS was remarkably variable among our patients with LS, from a few years to decades, confirming that LS may be misdiagnosed and undertreated. Severity of hypertension among our patients with LS ranged from mild to severe. Plasma potassium levels were low in the probands of families A and C but completely normal in the proband's sister of family C and in family B. The proband's sister of family C (C III-3) was normotensive at the beginning of our research but developed hypertension during the preparation of our article. Low plasma level of both renin and aldosterone was the only laboratory feature shared by the patients with LS belonging to the 3 families. Treatment with amiloride at a daily dose ranging from 5 to 20 mg resulted in normalization of blood pressure, correction of hypokalemia, or maintenance of normal potassium levels in those with pretreatment normokalemia and increase in plasma levels of renin and aldosterone ( Table 1) .
Comparison of mtDNA and Y chromosome showed different lineages between the lines (either maternal or paternal) carrying the β-P617L mutation (Table 2) . However, the probands' mtDNA haplotypes in families A and C are typical of people of Sicilian-Calabrian descent, suggesting a localized geographic origin in the provinces of Messina (Sicily, Italy) and Reggio Calabria (Calabria, Italy) based also on surname localization (data not shown to protect the anonymity of the probands). We, therefore, compared the total proportion of shared genome (using the PLINK-genome function) between pairs of affected samples and between affected and control samples to uncover relatedness at the genomic level. The proportion of genome shared by identity by descent in pairs of affected samples each belonging to a different family was comparable to the proportion of genome shared between these and the healthy controls (no comparison was above the top 1% of the empirical distribution). This confirms that the 3 LS families are not closely related at a genomic level, consistently with the mtDNA and Y chromosome results.
However, on closer inspection, the shared LS-causing allele tagged a genomic haplotype shared by all the 9 carriers, which spans 4.5 Mbps on chromosome 16 and encompasses a smaller core haplotype also detected among the healthy control samples ( Figure S2 ). Given its length, such a haplotype is unlikely to have arisen by chance in all 3 families and is therefore best explained as the 3 families sharing the LS-causing allele by common descent. We, therefore, chose to estimate the tMRCA of this haplotype and in turn used this date to estimate how many unsampled carriers to expect in the same population.
As a starting point, we selected the population of Messina and Reggio Calabria (shown to be a continuum from a biodemographic viewpoint, 33 total census size ≈1.2 million) as the source population of the 3 cases. The tMRCA for the disease allele-associated haplotype in these 3 families was estimated to have lived 13 (95% confidence interval: 1.4-37.6) generations ago ( Figure 2A ). By performing forward simulations conditioned on at least 3 carriers being present in today's generation, we estimate that 20 (95% highest posterior density: 3-69) carriers are present in the region of origin of the affected individuals ( Figure 2B ), 17 in addition to the already sampled probands and their relatives. This number is even larger (99; 95% highest posterior density: 3-193) when using an exponential rather than a hyperexponential function to model population growth in southern Italy. Therefore, we conservatively estimate the prevalence of the LS because of β-P617L mutation to be 20/1 200 000=1.67×10 -5 (95% highest posterior density: 2.5×10 -6 to 5.75×10 -5 ), which is at least 17× higher than the estimated prevalence of <1×10 -6 worldwide.
Discussion
Our findings show that, when ascertaining reportedly unrelated individuals belonging to a circumscribed population for the presence of a rare disease, the chances of discovering cryptic relatedness in the form of a long shared haplotype at the disease-causing locus are high. In the present study, we report that the 3 probands shared a common ancestor 13 generations ago. From a clinical viewpoint, our study confirms the variable expressivity of LS with regard to age at presentation, degree of hypertension, and plasma potassium concentration despite sharing the same causative allele. Both blood pressure and plasma potassium values can vary greatly among patients within the same pedigree, or unrelated patients with the same allele, presumably as a result of both allelic variants of other genes and different sodium and potassium intakes, which may modify the effects of the mutant alleles. 3, 22, 27 On the contrary, reduced plasma levels of renin associated with low-or normal values of plasma aldosterone are a common finding in patients with LS. One carrier of the β P617L allele (C IV-1) did not exhibit the LS phenotype. However, he was newly born (now 4 years old). Because LS usually manifests itself between the ages of 10 and 30 years, he could develop LS in the future. Alternatively, he could be spared from developing LS because LS alleles are The patients are indicated as in the Figure 1 . B IV-2 declined treatment and follow-up. C IV-1 was newly born at the time of genetic analysis. C III-3 developed hypertension 3 year after the genetic analysis. DBP indicates diastolic blood pressure; F, female; HT, hypertension; M, male; p[Aldo], plasma aldosterone in sitting position; PRA, plasma renin activity in sitting position; SBP, systolic blood pressure; and Tx, treatment with amiloride.
incompletely penetrant, even within the same kin. 3 Because this subject is actually at risk of LS, we have planned periodic monitoring of his blood pressure, plasma potassium values, and urinary sodium excretion (to check his intake of sodium).
Although LS is considered a rare condition, its prevalence in large cohorts of hypertensives has not been investigated to date. However, in 2 different cohorts of 330 and 766 Chinese patients with early-onset hypertension, the prevalence of LS genetically confirmed turned out to be 1.5% and 0.9%, respectively. Moreover, genetic screening of the probands' relatives identified many more cases with LS, as expected from the Mendelian dominant nature of the disease. 34, 35 These findings suggest that the prevalence of LS may not be as low as commonly reported. Moreover, one of the above studies 34 may have failed to identify some patients with LS because only the hypokalemic subjects of the cohort were selected for genetic testing. Indeed, plasma potassium concentration may range from severe hypokalemia to normal values both among patients with LS belonging to the same kin and among reportedly unrelated kin carrying the same allele 3, 27 as shown in the present study. This variability of plasma potassium concentration is reminiscent of other conditions characterized by increased activity of ENaC in primis primary aldosteronism. Indeed, screening of hypertensives for primary aldosteronism regardless of plasma potassium values has considerably increased the prevalence of this condition among hypertensives from <1% to >10% and showed that the majority of the patients are actually normokalemic. 36 By contrast, LS is currently considered exclusively in hypokalemic hypertensives while normokalemic patients with LS are identified only after the genetic screening of the relatives of hypokalemic probands. Thus, existing approaches may fail to diagnose and appropriately treat many normokalemic patients with LS. Therefore, LS should be taken into account in all patients with early-onset hypertension regardless of the plasma potassium concentration. Moreover, LS should be considered even in young hypertensives without a family history of early-onset hypertension because de novo mutations may be responsible for sporadic cases of LS. 20, 37, 38 More extensive searching for and earlier diagnosis of patients with LS are justified for several reasons. First, patients with misdiagnosed LS are at high risk of both cerebrovascular and cardiovascular events, including sudden death, and are unresponsive to both conventional antihypertensive drugs and mineralocorticoid receptor antagonists. Second, in many patients, diagnosis of LS is delayed by many years, and many more patients remain undiagnosed in their lifetime. Third, screening of the probands' relatives often leads to the identification of additional patients with LS, previously misdiagnosed and improperly treated. Last, ENaC blockers (amiloride and triamterene) together with dietary salt restriction are impressively efficient in both reversing the clinical manifestations and preventing the severe complications of LS.
Conclusions
With the present study, we infer the evolutionary history of the disease-causing allele detected in all 3 affected families, building on an approach developed for another successful prediction of underdiagnosed cases of a rare disease.
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Perspectives
We predict that a considerable number of undiagnosed cases may reside in the area of origin of these 3 families, which constitutes between a 17-and 82-fold increase in the prevalence (depending on the assumed underlying demographic model).
Our results suggest that evolutionary approaches combined with clinical data may increase the accuracy of epidemiological prediction, at least in original populations of circumscribed geographical areas, and contribute to the understanding of the prevalence and hopefully the ways in which we can improve the treatment of an otherwise underdiagnosed disease. 
